Study of CM326 in Healthy Men
Treatments studied
This study tests how a new investigational drug (called CM326) behaves in the body of healthy volunteers. It is a pharmacokinetic study, meaning it looks at how the drug is absorbed, distributed, and eliminated. Participation may help researchers understand the drug's safety and dosing for future studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a healthy man aged 18 to 55.
- Your weight must be between 55 and 85 kg, and your body mass index (BMI) between 19 and 26.
- You must be able to use reliable birth control (or have a partner who does) for 3 months after the dose.
- You cannot have any major chronic or severe conditions, or a history of drug or alcohol abuse.
- You must not have used any prescription or over-the-counter medications (including herbal supplements) within 14 days before dosing.
- You need to be willing to follow study rules, including avoiding smoking, alcohol, and caffeine beyond limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing how a new drug is processed by the body in healthy men. It will help researchers understand the drug's effects and safety before it is tested in patients.
This study tracks how a new drug, called FXS4640, moves through the body in healthy men. It uses a small amount of radioactivity to follow the drug, which helps researchers understand how it is absorbed and cleared. Participation involves staying at the clinic for several days for tests and samples.
This trial tests an investigational drug called CM326 for people with moderate to severe asthma that is not well controlled with current treatments. It aims to see if CM326 can help reduce asthma attacks and improve breathing.
This trial tests a new medicine called BCD-261 in healthy men to see if it is safe and how the body processes it. Participants will receive increasing doses and be monitored for about 4 months.
This is an early-stage safety test of a new investigational drug called HSK56630 in healthy volunteers with no major medical conditions. Researchers will monitor how your body tolerates the drug and what side effects might occur.
This trial is testing a new intravenous medicine (ME3241) for safety and how the body handles it. It's for healthy adults, so researchers can see how the drug works before testing it in people with the target condition.
Hear when a new Healthy Subjects trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.